Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BETRFNASDAQ:TRAWNASDAQ:TSBXOTCMKTS:VGLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBETRFBetterLife Pharma$0.06+5.0%$0.07$0.05▼$0.15$7.88M1.4521,571 shs16,216 shsTRAWTraws Pharma$1.45$1.47$0.97▼$19.44$8.06M1.46449,302 shs115,413 shsTSBXTurnstone Biologics$0.37+0.9%$0.35$0.29▼$2.69$8.45M1.35279,212 shs59,751 shsVGLSVG Life Sciences$0.00$0.00$0.00▼$0.00$2.11M1.678.22 million shs7.50 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBETRFBetterLife Pharma0.00%-4.45%-10.63%-0.68%-51.67%TRAWTraws Pharma0.00%0.00%-13.33%-24.74%+142,999,900.00%TSBXTurnstone Biologics0.00%+2.64%+0.28%-2.24%-83.84%VGLSVG Life Sciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBETRFBetterLife PharmaN/AN/AN/AN/AN/AN/AN/AN/ATRAWTraws Pharma0.1992 of 5 stars0.02.00.00.01.90.80.0TSBXTurnstone Biologics1.199 of 5 stars1.83.00.00.00.02.51.3VGLSVG Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBETRFBetterLife Pharma 0.00N/AN/AN/ATRAWTraws Pharma 0.00N/AN/AN/ATSBXTurnstone Biologics 1.50Reduce$0.4523.25% UpsideVGLSVG Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBETRFBetterLife PharmaN/AN/AN/AN/A($0.04) per shareN/ATRAWTraws Pharma$230K35.05N/AN/A($8.66) per share-0.17TSBXTurnstone Biologics$19.31M0.44N/AN/A$1.36 per share0.27VGLSVG Life SciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBETRFBetterLife Pharma-$2.55M-$0.01N/A∞N/AN/AN/A-609.07%9/23/2025 (Estimated)TRAWTraws Pharma-$166.52M-$32.81N/AN/AN/A-15,245.81%N/A-193.21%8/21/2025 (Estimated)TSBXTurnstone Biologics-$70.84M-$2.73N/AN/AN/AN/A-162.79%-124.10%8/13/2025 (Estimated)VGLSVG Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/ALatest VGLS, BETRF, TRAW, and TSBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025TRAWTraws Pharma-$8.04$2.09+$10.13$2.09$0.06 million$0.06 million5/8/2025Q1 2025TSBXTurnstone Biologics-$0.26-$0.51-$0.25-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBETRFBetterLife PharmaN/AN/AN/AN/AN/ATRAWTraws PharmaN/AN/AN/AN/AN/ATSBXTurnstone BiologicsN/AN/AN/AN/AN/AVGLSVG Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBETRFBetterLife PharmaN/A0.040.04TRAWTraws PharmaN/A1.811.81TSBXTurnstone BiologicsN/A3.703.70VGLSVG Life SciencesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBETRFBetterLife Pharma0.01%TRAWTraws Pharma7.95%TSBXTurnstone Biologics52.51%VGLSVG Life SciencesN/AInsider OwnershipCompanyInsider OwnershipBETRFBetterLife Pharma34.77%TRAWTraws Pharma13.60%TSBXTurnstone Biologics32.10%VGLSVG Life SciencesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBETRFBetterLife Pharma7129.46 million84.45 millionNot OptionableTRAWTraws Pharma175.56 million4.81 millionOptionableTSBXTurnstone Biologics8223.14 million15.71 millionNot OptionableVGLSVG Life Sciences121.10 billionN/ANot OptionableVGLS, BETRF, TRAW, and TSBX HeadlinesRecent News About These CompaniesVGLS VG Life Sciences Inc. - Seeking AlphaJune 28, 2025 | seekingalpha.comCamfil USA Unveils Absolute® VG: Advanced V-Bank HEPA Filters with Gasket and Gel SealsOctober 31, 2024 | markets.businessinsider.comVG Life Sciences Inc.September 14, 2024 | barrons.comVG Life Sciences, Inc. Increases Authorized SharesAugust 16, 2024 | br.advfn.comVG Life Sciences Inc. Moves to Restore Financial Accountability & Completes Prior Year Audits, Plans to File Form 10August 16, 2024 | br.advfn.comVG Life Sciences Inc. (VGLS)March 1, 2024 | finance.yahoo.comVG Life Sciences Stock (OTC:VGLS), Insider Trading ActivityFebruary 27, 2024 | benzinga.comEmerging from a Recent Pullback, Life Sciences Has a PulseJanuary 18, 2024 | globest.comGVG Life Sciences Inc VGLSNovember 16, 2023 | morningstar.comMReport warns of 'oversupply' of life sciences real estateSeptember 17, 2023 | bizjournals.comVGLS VG Life Sciences Inc.February 16, 2023 | seekingalpha.comThe best Life is Strange game is on PlayStation Plus right now – and it’s not what you thinkJanuary 26, 2023 | vg247.comVMedia Sentiment Over TimeVGLS, BETRF, TRAW, and TSBX Company DescriptionsBetterLife Pharma OTCMKTS:BETRF$0.06 +0.00 (+5.00%) As of 10:03 AM EasternBetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.Traws Pharma NASDAQ:TRAW$1.45 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.44 -0.01 (-0.69%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Turnstone Biologics NASDAQ:TSBX$0.37 +0.00 (+0.91%) Closing price 04:00 PM EasternExtended Trading$0.36 0.00 (-0.85%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.VG Life Sciences OTCMKTS:VGLS$0.0001 0.00 (0.00%) As of 02:04 PM EasternVG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
